The Priority Review

Category

Clinical trials

Trial starts, readouts, holds and designs.

267 stories · page 5 of 23

Stories

  1. Survodutide shows no increased cardiovascular risk in obesity trial

    The authors reported that in the SYNCHRONIZE-CVOT phase 3 trial, 136 of 3671 participants receiving survodutide experienced the primary composite endpoint versus 76 of 1836 receiving placebo (HR 0·89 [95% CI 0·67-1·18]). Gastrointestinal adverse events were more frequent with survodutide, with nausea in 48·0%-49·0% and vomiting in 31·7%-34·0% of participants.

  2. Tiragolumab and atezolizumab: median progression-free survival 7.00 vs 5.55 months

    In participants with high PD-L1 expression, median progression-free survival was 7.00 months with tiragolumab plus atezolizumab and 5.55 months with placebo plus atezolizumab. The record now holds randomized Phase III results for 620 participants with untreated non-small cell lung cancer.

  3. New Phase 3 trials registered, week of November 9, 2026: 14 industry trials

    Industry sponsors registered 14 Phase 3 trials on ClinicalTrials.gov in the week of November 9 to 15, 2026. They plan to enroll 4,867 participants in all; the largest, Pfizer's Berobenatide trial, plans to enroll 900.

  4. Anaheim Bio lève 40 millions d'euros en série A

    Anaheim Bio a annoncé un financement de série A sursouscrit de 40 millions d'euros, assuré par Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest et Thuja Capital. Le capital permettra de franchir les études préparatoires à l'IND et d'entrer en phase 1 pour l'ANA-1, un candidat thérapeutique contre la maladie de dépôt de pyrophosphate de calcium.

  5. CSPC Megalith Biopharmaceutical registers Phase III trial of enlonstobart with SYS6010

    The trial plans to enroll 585 participants, beginning on December 30, 2026, with a primary completion date of December 30, 2029. It is a randomized, controlled, double-blind, multicenter Phase III study evaluating the efficacy and safety of enlonstobart with or without SYS6010 in participants with pathologically residual esophageal squamous cell carcinoma after complete surgical resection.

  6. Ascendis Pharma registers Phase 3 trial of navepegritide and lonapegsomatropin in achondroplasia

    The study, led by Ascendis Pharma A/S, plans to enroll 144 participants and start in November 2026. It compares dual therapy with navepegritide and lonapegsomatropin to navepegritide monotherapy and lonapegsomatropin monotherapy in children and adolescents with achondroplasia.

  7. Hoffmann-La Roche posts results of Phase III tiragolumab trial in NSCLC

    The study, completed with 620 participants, compared tiragolumab plus atezolizumab to placebo plus atezolizumab in patients with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer. Primary completion occurred on December 30, 2025, and the trial was registered as NCT04294810.

  8. Medicare Drug Price Negotiation Program, RYBREVANT FASPRO, and Sanofi: the issue of November 2, 2026

    The week of November 2 to 8, 2026: 71 briefs, 17 stories, led by Medicare Drug Price Negotiation Program, RYBREVANT FASPRO, and Sanofi.

  9. Booster of rMenB+OMV NZ gave primed participants 3.89 times the fHbp titer of naïve participants

    In a 312-participant GlaxoSmithKline study aged 10 to 20 years, one booster dose in primed participants gave a fHbp hSBA titer ratio of 3.89 against the first dose in naïve participants at Day 31. The record now holds results for all four MenB indicator strains.

  10. Johnson & Johnson reports 73% PSA response rate in Phase 1 study

    Johnson & Johnson said that 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in PSA, and 47 percent (7 of 15 patients) achieved reductions of at least 90 percent. The company noted no Grade 3 or higher treatment-related adverse events in this early analysis.

  11. 42.3 percent on povorcitinib reached HiSCR50 at Week 12 versus 28.6 percent on placebo

    In the Phase 3 STOP-HS2 study of 619 participants with moderate to severe hidradenitis suppurativa, 42.3 percent on povorcitinib 45 mg and 42.3 percent on 75 mg reached HiSCR50 at Week 12, against 28.6 percent on placebo. Incyte Corporation's results are now posted in the trial registry.

  12. Johnson & Johnson releases new Phase 2 nipocalimab data in Sjögren's disease

    Johnson & Johnson said the Phase 2 DAHLIAS study found that mouth dryness was the most important symptom to improve, with 96% of patients citing it. The study also reported that at least 50% improvement in objective salivary flow was observed in more than twice as many patients receiving 15 mg/kg nipocalimab compared with placebo (33% versus 16%) at Week 24.